Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 7/20 | 0.61 |
| ▸ | S1PR1 | P21453 | 8/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.45 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23524062 | 1.00 | XDH (0.61) | XDHS1PR1CYP2D6PGRAR | |
| SCHEMBL23524302 | 0.82 | PDE10A (0.45) | XDHS1PR1CYP2D6PGRAR | |
| SCHEMBL30355381 | 0.82 | PDE10A (0.45) | XDHS1PR1CYP2D6PGRAR | |
| SCHEMBL23523838 | 0.81 | XDH (0.63) | XDHS1PR1CYP2D6 | |
| SCHEMBL30355449 | 0.81 | XDH (0.63) | XDHS1PR1CYP2D6 | |
| SCHEMBL23523762 | 0.80 | PGR (0.48) | S1PR1PGRAR | |
| SCHEMBL30355464 | 0.80 | PGR (0.48) | S1PR1PGRAR | |
| SCHEMBL2409319 | 0.79 | XDH (0.71) | XDHS1PR1CYP2D6S1PR3 | |
| SCHEMBL23523942 | 0.79 | XDH (0.67) | XDHS1PR1CYP2D6 | |
| SCHEMBL23523734 | 0.78 | XDH (0.63) | XDHS1PR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230114241-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | TREVENA, INC. | 2023-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | XDH 4416/4885S1PR1 1/4885CYP2D6 4598/4885 |
| US-20230114241-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | S1PR1, S1PR2, S1PR3 | XDH 3320/4885S1PR1 1/4885CYP2D6 4320/4885 |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | S1PR1, S1PR2, S1PR3 | XDH 4416/4885S1PR1 1/4885CYP2D6 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.